

BioSpect


the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Roche Pharma launches Tecentriq® SC, India's first subcutaneous immunotherapy for lung cancer in India

14 May 2026 | News

Approved in 85 countries, 10,000+ patients benefitted globally



Roche Pharma India has announced the launch of Tecentriq® (atezolizumab) SC in India, the country's first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately 7 minutes, compared to conventional IV infusions that can take hours.

By reducing treatment administration time to approximately 7 minutes, Tecentriq SC is a breakthrough innovation that has the potential to dramatically improve the cancer treatment experience of patients — reducing treatment time by ~80%, lowering indirect treatment costs, minimising the need to travel long distances, and enabling and caregivers spend less time in hospitals and more time doing what they love.

Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers. First approved by the MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitted globally.

Clinical studies have demonstrated comparable efficacy and safety to IV Tecentriq while enabling a significantly faster and significantly more convenient treatment experience. In India, Tecentriq SC as of now is approved by DCGI for adjuvant & metastatic Lung Cancer (NSCLC).